Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis
The higher incidence of DAOSD in AD patients compared with SA patients in this real-world study highlights the importance of physician awareness, especially when prescribing dupilumab to AD patients. Conversely, the findings of this study help alleviate potential concerns about ocular AEs in patients with SA who do not have comorbid AD. Furthermore, the effective management of most ocular AEs with ophthalmic treatments suggests favorable tolerability of dupilumab in daily practice, and multidisciplinary collaboration is essential to proactively manage ocular AEs before discontinuing dupilumab.
Authors
- Tamar E. C. Nijsten (ORCID: https://orcid.org/0000-0001-9940-2875)
- Anne R. Schlösser (ORCID: https://orcid.org/0000-0003-0449-6077)
- J.C.C.M. in ’t Veen (ORCID: https://orcid.org/0000-0001-6828-2612)
- Gert‐Jan Braunstahl (ORCID: https://orcid.org/0000-0001-7671-3742)
- Alberta A. H. J. Thiadens (ORCID: https://orcid.org/0000-0002-4911-9462)
- John C. Thelen
- DirkJan Hijnen (ORCID: https://orcid.org/0000-0003-3379-3425)
- Renske Schappin (ORCID: https://orcid.org/0000-0002-5727-5852)
- Lotte Bult (ORCID: https://orcid.org/0009-0000-1835-3195)
Institutions
- Erasmus MC (NL)
- Sint Franciscus Gasthuis (NL)
Publication Details
- Journal
- Clinical and Translational Allergy
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/clt2.12386
- Citations
- 5
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.67
Funders
- Sanofi
- Sanofi Genzyme